Absci (ABSI) Stock News
$ABSI · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Absci (ABSI) in the past 30 days. BORSA’s news read on ABSI is bullish at 67/100, based on 1 company event over the past 7 days. ABSI last closed at $9.14 on Nov 12, down 2.72% over five sessions and up 4.52% over the past month.
The wire on $ABSI
newest first · updated · direct subject stories onlyAbsci appointed former Galderma executive Gerry Muhle as Chief Commercial Officer. The company also reported Q3 2026 financial results and confirmed ABS-201 trial progress: 13-week interim data expected December 2026, full data early 2027. Phase 2 endometriosis trial planned for mid-2027. Cash runway into H2 2028.
bullish 65 · impact 60Absci announced plans for a Phase 2 trial of its AI-designed antibody ABS-201 in endometriosis. The double-blind, placebo-controlled study targets approximately 150 surgically diagnosed patients with moderate to severe pain across 10+ countries. Primary endpoints are reductions in dysmenorrhea and non-menstrual pelvic pain. Initiation is expected in mid-2027, subject to regulatory clearance and protocol finalization.
